Randy Mills
Advisory Board Member
Dr. Randy Mills is CEO of Aziyo Biologics. Randy is a transformational leader whose work has shaped biotechnology and improved lives. Throughout his career he has generated significant economic growth, taking three companies public, resulting in over $1 billion in shareholder value. As CEO of Osiris Therapeutics (Nasdaq: OSIR), he commercialized five cell therapy products responsible for $1.5 billion in cumulative sales. Starting out, the subject of his graduate research, BioCleanse, became the core technology that launched Regeneration Technologies (Nasdaq: RTIX). Technologies Dr. Mills invented throughout his career have been used in the treatment of over 10 million patients.
Randy’s "patient first” leadership style has also helped transform some of medicine's most respected and important organizations. As President of the California Institute for Regenerative Medicine, he radically improved the speed and transparency of the $8.5 billion agency. As CEO of the National Marrow Donor Program/Be The Match, he launched a bold plan to Democratize Cell Therapy, resulting in significantly more bone marrow matches for ethnically diverse patients.
A sought-after speaker, his accomplishments have been chronicled in the Wall Street Journal, The New York Times, Forbes, and LA Times, and he has appeared on CNBC, Fox Business News, and Bloomberg. Dr. Mills has been widely recognized, including being named an Ernst & Young Entrepreneur of the Year, listed as one of the World's 50 Most Influential People in Regenerative Medicine, selected to ring the closing bell of NASDAQ, and winner of the Hyatt Memorial Award for Scientific Leadership in Transplantation.